| [1] |
Hou JH, Zhu HX, Zhou ML, et al. Changes in the spectrum of kidney diseases: an analysis of 40，759 biopsy-proven cases from 2003 to 2014 in China [J]. Kidney Dis (Basel), 2018, 4(1): 10-19.
|
| [2] |
Couser WG. Primary membranous nephropathy [J]. Clin J Am Soc Nephrol, 2017, 12(6): 983-997.
|
| [3] |
Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease [J]. Clin J Am Soc Nephrol, 2012, 7(3): 513-520.
|
| [4] |
Bellomo R, Wood C, Wagner I, et al. Idiopathic membranous nephropathy in an Australian population: the incidence of thromboembolism and its impact on the natural history [J]. Nephron, 1993, 63(2): 240-241.
|
| [5] |
Lionaki S, Derebail VK, Hogan SL, et al. Venous thromboembolism in patients with membranous nephropathy [J]. Clin J Am Soc Nephrol, 2012, 7(1): 43-51.
|
| [6] |
Kumar S, Chapagain A, Nitsch D, et al. Proteinuria and hypoalbuminemia are risk factors for thromboembolic events in patients with idiopathic membranous nephropathy: an observational study [J]. BMC Nephrol, 2012, 13: 107.
|
| [7] |
Li SJ, Guo JZ, Zuo K, et al. Thromboembolic complications in membranous nephropathy patients with nephrotic syndrome-a prospective study [J]. Thromb Res, 2012, 130(3): 501-505.
|
| [8] |
Gregson J, Kaptoge S, Bolton T, et al. Cardiovascular risk factors associated with venous thromboembolism [J]. JAMA Cardiol, 2019, 4(2): 163-173.
|
| [9] |
Eneman B, Levtchenko E, van den Heuvel B, et al. Platelet abnormalities in nephrotic syndrome [J]. Pediatr Nephrol, 2016, 31(8): 1267-1279.
|
| [10] |
Eneman B, Elmonem MA, van den Heuvel LP, et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) in zebrafish models of nephrotic syndrome [J]. PLoS One, 2017, 12(7): e0182100.
|
| [11] |
Eneman B, Freson K, van den Heuvel L, et al. Pituitary adenylate cyclase-activating polypeptide deficiency associated with increased platelet count and aggregability in nephrotic syndrome [J]. J Thromb Haemost, 2015, 13(5): 755-767.
|
| [12] |
Barbour SJ, Greenwald A, Djurdjev O, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis [J]. Kidney Int, 2012, 81(2): 190-195.
|
| [13] |
Hamano K, Iwano M, Akai Y, et al. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis [J]. Am J Kidney Dis, 2002, 39(4): 695-705.
|
| [14] |
Gao C, Xie R, Yu C, et al. Procoagulant activity of erythrocytes and platelets through phosphatidylserine exposure and microparticles release in patients with nephrotic syndrome [J]. Thromb Haemost, 2012, 107(4): 681-689.
|
| [15] |
Wang GH, Lu J, Ma KL, et al. The release of monocyte-derived tissue factor-positive microparticles contributes to a hypercoagulable state in idiopathic membranous nephropathy [J]. J Atheroscler Thromb, 2019, 26(6): 538-546.
|
| [16] |
Chen G, Liu H, Liu F. A glimpse of the glomerular milieu: from endothelial cell to thrombotic disease in nephrotic syndrome [J]. Microvasc Res, 2013, 89: 1-6.
|
| [17] |
Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome [J]. Kidney Int, 1985, 28(3): 429-439.
|
| [18] |
Beck LH Jr, Salant DJ. Refining our understanding of the PLA2R-antibody response in primary membranous nephropathy: looking forward, looking back [J]. J Am Soc Nephrol, 2020, 31(1): 8-11.
|
| [19] |
刘蕾，乐伟波，徐孝东，等. 特发性膜性肾病凝血功能障碍与血小板功能亢进的关联[J]. 肾脏病与透析肾移植杂志，2017, 26(2): 108-112,152.
|
| [20] |
Gyamlani G, Molnar MZ, Lu JL, et al. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome [J]. Nephrol Dial Transplant, 2017, 32(1): 157-164.
|
| [21] |
金金，王亚红，王红燕，等. 肾静脉栓塞的彩色多普勒超声征象及其诊断价值[J/CD]. 中华医学超声杂志(电子版), 2018, 15(4): 258-262.
|
| [22] |
Kim JH, Lim KM, Gwak HS. New anticoagulants for the prevention and treatment of venous thromboembolism [J]. Biomol Ther (Seoul), 2017, 25(5): 461-470.
|
| [23] |
Beck L, Bomback AS, Choi MJ, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis [J]. Am J Kidney Dis, 2013, 62(3): 403-441.
|
| [24] |
Medjeral-Thomas N, Ziaj S, Condon M, et al. Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome [J]. Clin J Am Soc Nephrol, 2014, 9(3): 478-483.
|
| [25] |
Eneman B, Levtchenko E, van den Heuvel B, et al. Platelet abnormalities in nephrotic syndrome [J]. Pediatr Nephrol, 2016, 31(8): 1267-1279.
|
| [26] |
Lee T, Biddle AK, Lionaki S, et al. Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy [J]. Kidney Int, 2014, 85(6): 1412-1420.
|
| [27] |
Kelddal S, Nykjær KM, Gregersen JW, et al. Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications [J]. BMC Nephrol, 2019, 20(1): 139.
|
| [28] |
Sexton DJ, de Freitas DG, Little MA, et al. Direct-acting oral anticoagulants as prophylaxis against thromboembolism in the nephrotic syndrome [J]. Kidney Int Rep, 2018, 3(4): 784-793.
|
| [29] |
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report [J]. Chest, 2016, 149(2): 315-352.
|
| [30] |
Zhang L, Zhang H, Zhang J, et al. Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: a pilot study [J]. Exp Ther Med, 2018, 15(1): 739-744.
|
| [31] |
Reynolds ML, Nachman PH, Mooberry MJ, et al. Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy [J]. J Nephrol, 2019, 32(4): 669-672.
|
| [32] |
Lim HY, O′Malley C, Donnan G, et al. A review of global coagulation assays-is there a role in thrombosis risk prediction? [J]. Thromb Res, 2019, 179: 45-55.
|
| [33] |
Hincker A, Feit J, Sladen RN, et al. Rotational thromboelastometry predicts thromboembolic complications after major non-cardiac surgery [J]. Crit Care, 2014, 18(5): 549.
|
| [34] |
Brill JB, Badiee J, Zander AL, et al. The rate of deep vein thrombosis doubles in trauma patients with hypercoagulable thromboelastography [J]. J Trauma Acute Care Surg, 2017, 83(3): 413-419.
|